Výsledky vyhledávání - Vadim Kozlov
- Zobrazuji výsledky 1 - 6 z 6
-
1
-
2
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) Autor Jonathan E. Rosenberg, Se Hoon Park, Vadim Kozlov, Tu Van Dao, Daniel Castellano, Jian‐Ri Li, Som D. Mukherjee, Kathryn Howells, Hannah Dry, Mark C. Lanasa, Ross Stewart, Dean F. Bajorin
Vydáno 2022Artigo -
3
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Adva... Autor Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, Vadim Kozlov, Teresa Alonso‐Gordoa, Masatoshi Eto, Thomas E. Hutson, Robert J. Motzer, Eric Winquist, Pablo Maroto, Bhumsuk Keam, Giuseppe Procopio, Shirley Wong, Bohuslav Melichar, Frédéric Rolland, Mototsugu Oya, Karla Rodriguez-Lopez, Kenichi Saito, Jodi A. McKenzie, Camillo Porta
Vydáno 2023Artigo -
4
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Autor Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Vydáno 2021Artigo -
5
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial Autor Renato D. Lópes, Celestia S. Higano, Susan F. Slovin, Adam J. Nelson, Robert Bigelow, Per Settergren Sørensen, Chiara Melloni, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson, Deepak L. Bhatt, Noel W. Clarke, Tine Kold Olesen, Belinda T. Doyle-Olsen, Henriette Kristensen, Lauren Arney, Matthew T. Roe, John H. Alexander, Mirjam Mol-Arts, Samreen Mansor-Lefebvre, Konstantin Zubovskiy, Allan Blemings, Klaus A. Dugi, Gerald S. Bloomfield, Chris Kontos, Adam D. DeVore, J. Dedrick Jordan, Brad J. Kolls, J. B. Matthews, Rajendra H. Mehta, Thomas J. Povsic, Michael Morse, Kenneth W. Mahaffey, Susan Halabi, Darryl P. Leong, Laurence Klotz, Neil Fleshner, G. Kenneth Jansz, Jonathan Giddens, R. Blair Egerdie, Joseph L. Chin, Joseph Zadra, Richard Casey, Jean Simard, Tamim Niazi, André‐Guy Martin, Marek Babjuk, Jaroslav Hájek, Jiří Klečka, Jiří Kubeš, Jan Schraml, Jitka Jakesova, J Vaňásek, Bohuslav Melichar, Heikki Seikkula, M. Abdiche, Marc Colombel, P. Debourdeau, G. Robert, Arnauld Villers, Guillaume Ploussard, Benjamin Pradère, F. Bruyère, Jean‐Luc Descotes, I. Ouzaïd, Alexander Winter, Herbert Hanitzsch, H. Sperling, Ralf Eckert, Peter Hammerer, E. Stagge, F. Seseke, Silvio Szymula, Aristotelis Bamias, A. Thanos, Konstantinos Hatzimouratidis, Charalambos Mamoulakis, Haralabos P. Kalofonos, Elżbieta Oszukowska, Katarzyna Madziarska, Jacek Fijuth, Mateusz Obarzanowski, B. Yа. Alekseev, Vagif Atduev, Pushkar' DIu, Evgeniy Veliev, A. V. Zyryаnov, С Б Петров, Evgeny Kopyltsov, Vadim Kozlov, Ladislav Macko, J. Dúbravický, Richard Polak, Obaidullah Mir, Marek Vargovcak, I. Minčík, J. Kliment, Frederico Gonçalves, J Mikuláš, Roman Sokol
Vydáno 2021Artigo -
6
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Autor Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez-Vidal, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler, Petra Holečková
Vydáno 2024Artigo
Vyhledávací nástroje:
Související témata
Cancer
Internal medicine
Medicine
Oncology
Immunotherapy
Lenvatinib
Pembrolizumab
Renal cell carcinoma
Sunitinib
Biochemistry
Clinical trial
Everolimus
Gene
Gynecology
Phases of clinical research
Randomized controlled trial
Thyroid cancer
Urology
Biology
Bladder cancer
Chemistry
Clinical endpoint
Confidence interval
Discontinuation
Durvalumab
Hazard ratio
Hepatocellular carcinoma
Kidney cancer
Meta-analysis
Metastatic Urothelial Carcinoma